# 2-HOBA in Systemic Lupus Erythematosus

> **NCT07225543** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 42 (estimated)

## Conditions studied

- Systemic Lupus Erthematosus (SLE)

## Interventions

- **DRUG:** 2-HOBA acetate (2-Hydroxybenzlamine acetate)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07225543
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2030-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07225543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07225543, "2-HOBA in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07225543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*